Conversion from amlodipine to felodipine ER: Did the change fulfill expectations?

Formulary

Volumn 35, Issue 5, 2000, Pages 435-442

  Oatis, Ghitiana M ^a,b   Stowers, Allan D ^c,d  

^a Maxwell Gunter AFB   (United States)

^b Barksdale Air Force Base   (United States)

^c PFIZER INC   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; AMLODIPINE BESYLATE; FELODIPINE;

ADULT; AGED; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; DRUG UTILIZATION; FEMALE; HUMAN; MALE; REVIEW; SUSTAINED DRUG RELEASE;

EID: 0342657675     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Kaplan RC, Psaty BM, Kriesel D, et al. Replacing short-acting nifedipine with alternative medications at a large health maintenance organization. Am J Hypertens 1998; 11:471-7.
2. Alexis G, Sessler NE, Conlin PR. Safety and efficacy of a mandatory formulary switch from nifedipine GITS to amlodipine. J Managed Care Pharm. In press.
3. Myers MG, Toal CB. Comparative efficacy of two long-acting formulations of nifedipine in the treatment of hypertension. The Switch Study Investigators. Can J Cardiol 1995;11:913-7.
4. Gustin G, White WB, Taylor S, Daragjati C. Clinical outcome of a mandatory formulary switch for dihydropyridine calcium channel blocker therapy at a Veteran's Administration medical center. Am J Hypertens 1996;9:312-6.
5. Kranz SR, Rase RS, Piepho RW. Retrospective analysis of formulary transition at large metropolitan HMO: Nifedipine GITS to felodipine ER. J Managed Care Pharm 1996;2:642-6.
6. Landry FJ, Horwhat JD, Tomich D, Pinski L. Felodipine as an alternative to more expensive calcium antagonists in mild to moderate hypertension. South Med J 1996; 89:573-7.
7. Burges RA, Dodd MG. Amlodipine. Cardiovasc Drug Rev 1990;8:25-44.
8. Mroczek WJ, Burris JF, Allenby KS. A double-blind evaluation of the effect of amlodipine on ambulatory blood pressure in hypertensive patients. J Cardiovasc Pharmacol 1988;12(Suppl 7):S79-84.
9. Weber MA, Goldberg AI, Faison EP, et al. Extended-release felodipine in patients with mild to moderate hypertension. Felodipine ER Dose-Response Study Group. Clin Pharmacol Ther 1994;55:346-52.
10. Welin L, Elvelin L, Niklasson A, et al. Overview of the safety of felodipine based on clinical trials in patients with hypertension. Am J Cardiol 1997;79:996-9.
11. Fagan TC, Haggert BE, Liss C. Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension. Clin Ther 1994;16:634-46.
12. Videbaek LM, Jacobsen IA. Crossover comparison of the pharmacokinetics of amlodipine and felodipine ER in hypertensive patients. Int J Clin Pharmacol Ther 1997; 35:514-8.
13. Bainbridge AD, Herlihy O, Meredith PA, Elliott HL. A comparative assessment of amlodipine and felodipine ER: Pharmacokinetic and pharmacodynamic indices. Eur J Clin Pharmacol 1993;45:425-30.
14. Östergren J, Isaksson H, Brodin U, et al. Effect of amlodipine versus felodipine extended release on 24-hour ambulatory blood pressure in hypertension. Am J Hypertens 1998;11:690-6.
15. Van Der Krogt JP, Brand R, Dawson EC on behalf of the Amfortas Study Group. Amlodipine versus extended-release felodipine in general practice: A randomized, parallel-group study in patients with mild-to-moderate hypertension. Curr Ther Res 1996; 57:145-58.
16. Leenen FH. Clinical relevance of 24 h blood pressure control by 1,4-dihydropyridines. Am J Hypertens 1996;9:97S-104S.
17. Rose M, McMahon FG. Some problems with antihypertensive drug studies in the context of the new guidelines. Am J Hypertens 1990;3:151-5.
18. Lefebvre J, Poirier L, Archambault F, et al. Comparative effects of felodipine ER, amlodipine and nifedipine GITS on 24 h blood pressure control and trough to peak ratios in mild to moderate ambulatory hypertension: A forced titration study. Can J Cardiol 1998;14:682-8.
19. Smilde JG. A comparison of amlodipine and felodipine extended release in the treatment of hypertension at steady state and after two missed doses. Curr Ther Res 1997;58:141-53.